Earnings
Home›Earnings›Results›We're raising our price target on Eli Lilly as the obe…
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
← Newer storyCruise companies aim to keep fuel costs down. Their strategies for do…Older story →Gold falls near $4,000 as strong US GDP fuels Fed hike outlook